Hyperuricemia Medical Services in China

Hyperuricemia is a metabolic disorder characterized by elevated serum uric acid (SUA) levels—defined as >6.8 mg/dL (>405 µmol/L) in adults—beyond the physiological saturation threshold for monosodium urate crystallization. It arises from an imbalance between uric acid production and excretion, primarily driven by impaired renal urate clearance (accounting for ~90% of cases) or, less commonly, overproduction due to purine metabolism dysregulation (e.g., PRPS1 mutations, HGPRT deficiency, or high-purine diets). Pathophysiologically, hyperuricemia triggers low-grade systemic inflammation via NLRP3 inflammasome activation, endothelial dysfunction, oxidative stress, and renin-angiotensin system upregulation—linking it mechanistically to hypertension, chronic kidney disease (CKD), insulin resistance, cardiovascular disease, and gout. Epidemiologically, prevalence has risen globally alongside urbanization and dietary shifts: current estimates indicate ~14–24% of adults in China have hyperuricemia, with higher rates among men (20–30%) than women (10–15%), and sharp increases after age 40. Key modifiable risk factors include obesity (especially abdominal adiposity), excessive alcohol intake (particularly beer and spirits), high-fructose beverages, red meat and seafood consumption, diuretic use (e.g., thiazides), chronic kidney disease, metabolic syndrome, and hypothyroidism. Non-modifiable risks include male sex, aging, genetic predisposition (e.g., SLC2A9, ABCG2 variants), and familial history. Importantly, hyperuricemia is often asymptomatic for years—yet persistent elevation (>7 mg/dL) significantly increases lifetime gout risk (up to 20% at 5 years, >50% at 20 years) and accelerates CKD progression. Beyond physical morbidity, it substantially impairs quality of life: patients report fatigue, joint stiffness, sleep disruption, anxiety about gout flares, reduced work productivity, dietary restrictions causing social isolation, and long-term concerns about kidney failure or cardiovascular events. Early detection and individualized management—including lifestyle modification, uricosurics (e.g., benzbromarone), or xanthine oxidase inhibitors (e.g., febuxostat, allopurinol)—are critical not only to prevent gout but also to mitigate multisystem end-organ damage. Rheumatology and immunology departments play a central role in diagnosis, risk stratification (e.g., 24-hour urinary uric acid testing, renal function assessment), and longitudinal care, especially given the frequent comorbidity with autoimmune rheumatic diseases such as psoriatic arthritis and lupus nephritis.

Hyperuricemia—a serum uric acid concentration exceeding 6.8 mg/dL (405 µmol/L) in men and postmenopausal women, or 5.7 mg/dL (340 µmol/L) in premenopausal women—is a metabolic disorder characterized by impaired purine metabolism or reduced renal urate excretion. While often asymptomatic, persistent hyperuricemia is the biochemical prerequisite for gout, uric acid nephrolithiasis, chronic kidney disease (CKD), and cardiovascular morbidity. Management in the Department of Rheumatology and Immunology emphasizes risk stratification: asymptomatic individuals require intervention only if serum uric acid exceeds 9.0 mg/dL, or if comorbidities such as hypertension, CKD stage ≥2, diabetes mellitus, or cardiovascular disease are present. Treatment goals include sustained serum uric acid reduction to <6.0 mg/dL (or <5.0 mg/dL in patients with tophaceous gout or frequent flares), prevention of crystal deposition, and mitigation of systemic inflammatory sequelae.

Conservative treatment forms the cornerstone of management and must be initiated concurrently with pharmacotherapy. Dietary modification targets modifiable purine load and insulin resistance: patients should limit intake of high-purine foods—including red meat, organ meats, shellfish, and yeast extracts—while avoiding fructose-sweetened beverages and excessive alcohol (particularly beer and spirits). Increased consumption of low-fat dairy products, cherries (rich in anthocyanins with uricosuric and anti-inflammatory properties), and plant-based proteins is encouraged. Hydration remains critical; daily fluid intake should exceed 2 L to promote uric acid dilution and reduce nephrolithiasis risk. Weight management is essential: gradual weight loss (0.5–1.0 kg/week) via caloric restriction and aerobic exercise improves insulin sensitivity and reduces uric acid production. However, rapid weight loss or ketogenic diets must be avoided due to ketosis-induced uric acid retention. Patients with hypertension or CKD should adhere strictly to sodium restriction (<2 g/day) and avoid diuretics unless clinically indispensable.

Pharmacologic therapy is indicated for recurrent gout attacks (>2/year), tophi, uric acid nephrolithiasis, or CKD stage ≥3. First-line urate-lowering therapy (ULT) is allopurinol, a xanthine oxidase inhibitor. Initiation at low doses (100 mg/day in normal renal function; 50 mg/day in eGFR <60 mL/min/1.73m²) minimizes hypersensitivity risk, with gradual titration every 2–4 weeks based on serum uric acid monitoring until target is achieved. Febuxostat serves as an alternative in patients intolerant or nonresponsive to allopurinol, particularly those with moderate renal impairment; however, cardiovascular safety requires careful assessment in patients with established ischemic heart disease. For underexcretors (fractional excretion of uric acid <5%), uricosurics—including probenecid (contraindicated in urolithiasis or eGFR <50 mL/min/1.73m²) and lesinurad (used adjunctively with xanthine oxidase inhibitors)—may be considered. Topiroxostat, a newer non-purine xanthine oxidase inhibitor approved in China, offers favorable pharmacokinetics and lower hypersensitivity incidence. During ULT initiation, prophylactic anti-inflammatory therapy (e.g., low-dose colchicine 0.5–0.6 mg once or twice daily for 6 months) is mandatory to prevent acute gout flares triggered by crystal mobilization. NSAIDs or low-dose glucocorticoids may substitute in colchicine-intolerant patients.

Surgical treatment plays a highly selective role and is never indicated for hyperuricemia alone. Indications are exclusively mechanical or structural: large, painful, or ulcerating tophi causing joint deformity, nerve compression (e.g., carpal tunnel syndrome), or functional impairment unresponsive to ≥6 months of optimized ULT. Surgical excision—typically performed under regional anesthesia with meticulous soft-tissue handling—requires concurrent optimization of serum uric acid to <5.0 mg/dL for ≥6 months preoperatively to minimize recurrence. Arthroscopic debridement may be employed for intra-articular tophi with synovitis. Nephrolithiasis necessitates urologic intervention (e.g., extracorporeal shockwave lithotripsy or ureteroscopy) only when stones cause obstruction, infection, or intractable pain; asymptomatic radiolucent uric acid stones are managed medically with urinary alkalinization (target pH 6.2–6.9) and hydration. Surgery does not replace medical therapy; rather, it complements long-term urate control.

Treatment advantages in China reflect integrated clinical infrastructure, regulatory agility, and epidemiologic responsiveness. The National Health Commission’s 2023 Clinical Practice Guidelines for Hyperuricemia and Gout emphasize standardized, tiered care across primary, secondary, and tertiary hospitals, with rheumatology-led multidisciplinary clinics incorporating nephrology, endocrinology, and nutrition support. China’s robust pharmaceutical innovation ecosystem has accelerated approval of domestically developed agents: topiroxostat received NMPA approval in 2021, and novel uricosurics (e.g., dotinurad analogs) are in late-phase trials. Real-world evidence from the China Gout Registry demonstrates superior adherence and target attainment rates (78% at 12 months) in patients managed within designated gout centers versus community care. Furthermore, AI-assisted decision support tools embedded in electronic health records enable dynamic dose titration and flare-risk prediction using longitudinal uric acid trajectories and comorbidity weighting. Traditional Chinese Medicine (TCM) adjuncts—such as Tongfengling granules (containing Smilax glabra and Atractylodes macrocephala)—are prescribed per integrated protocols for their demonstrated anti-inflammatory and mild uricosuric effects, though always as adjuncts to evidence-based ULT.

Recovery and long-term management hinge on patient empowerment and structured follow-up. Serum uric acid must be monitored every 2–4 weeks during ULT titration, then quarterly once stable. Renal function, liver enzymes, and complete blood count require biannual assessment. Patients should maintain a symptom diary documenting flares, medication adherence, dietary deviations, and precipitants (e.g., trauma, illness). Annual dual-energy CT (DECT) scanning is recommended for tophus burden quantification in refractory cases. Lifestyle counseling must be repeated at each visit, emphasizing that hyperuricemia is a chronic, relapsing condition requiring lifelong surveillance—not episodic intervention. Psychosocial support addresses stigma associated with gout and fosters self-efficacy. Finally, vaccination against influenza and pneumococcus is advised given the heightened infection risk in patients with chronic inflammation and/or immunomodulatory therapy. With comprehensive, individualized, and sustained intervention, hyperuricemia is not merely controllable—it is preventable in its most destructive manifestations.